Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. The present invention also relates to methods for treating diabetes, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases, comprising administering an SGLT2 inhibitor and a dipeptidyl peptidase IV (DPP IV) inhibitor.本發明提供經由共同投與二肽基肽酶IV(DPP IV)抑制劑來避免與投與葡萄糖鈉共輸送體2(SGLT2)抑制劑相關之升糖素分泌增加之方法。另外,提供經由共同投與二肽基肽酶IV(DPP IV)抑制劑使與投與葡萄糖鈉共輸送體2(SGLT2)抑制劑相關之該升糖素分泌正常化之方法。本發明亦關於治療糖尿病,尤其2型糖尿病,以及高血糖症、高胰島素血症、肥胖症、高三酸甘油酯血症、症候群X、糖尿病併發症、動脈粥樣硬化及相關疾病之方法,其包含投與SGLT2抑制劑及二肽基肽酶IV(DPP IV)抑制劑。
